Compounded GIP/GLP-1 with tirzepatide is a once-weekly injectable that acts on two metabolic pathways, GIP and GLP-1, unlike single-pathway GLP-1 drugs. It is prescribed for weight management and appetite control under virtual provider supervision. Users often report reduced appetite and less food preoccupation, but it is a compounded product, not FDA-approved, so purity and dosing can vary by pharmacy. It suits adults seeking a dual-action option who are comfortable with telehealth and self-injection.
In stockReturn policy
Users of compounded tirzepatide often report significant appetite suppression and weight loss, but experiences vary by pharmacy and some report side effects or inconsistent potency.
Compounded GIP/GLP-1 is a once-weekly injectable that contains tirzepatide. It acts on two pathways, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). A single-pathway GLP-1 compound acts on only one receptor. It targets appetite and metabolic signaling together, under medical supervision.
It is a compounded formulation made by a US-licensed 503A pharmacy. It is not a brand-name medication. Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety or effectiveness. It is available only with valid clinical authorization from a licensed provider, who reviews your health profile first.
It is taken as a once-weekly subcutaneous injection, and supplies are included. Dosing starts low and increases gradually under provider supervision to ease digestive side effects that some people feel early on. Slower gastric emptying helps you feel full on smaller portions. Results vary.
